Caribou Biosciences, Inc. (CRBU) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Caribou Biosciences reported revenue of $11.2M, up 11.7% from $10.0M the year before. Net income was -$148.1M (a -1327.4% net margin), or -$1.59 per diluted share. Operating margin was -1329.4%. Operating activities generated -$111.0M of cash, leaving -$112.4M of free cash flow. At fiscal year end, Caribou Biosciences held $175.4M in total assets against $53.2M in total liabilities, including $12.4M of cash and equivalents.
Open the full interactive Caribou Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Caribou Biosciences Key Stats
| Share Price | $0.47 |
|---|---|
| Market Cap | $47.5M |
| Revenue YoY Growth | +11.7% |
| 52-Week Range | $0.46 – $2.84 |
| Shares Outstanding | 101.0 million (basic, 2026 Q2) |
Caribou Biosciences Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $9.6M | $13.9M | $34.5M | $10.0M | $11.2M |
| Operating Income | -$67.0M | -$106.4M | -$116.1M | -$166.6M | -$148.3M |
| Pre-Tax Income | -$66.6M | -$99.4M | -$101.9M | -$149.1M | -$148.7M |
| Income Tax | $321,000 | $70,000 | $193,000 | -$9,000 | -$550,000 |
| Net Income | -$66.9M | -$99.4M | -$102.1M | -$149.1M | -$148.1M |
| Diluted EPS | -$2.11 | -$1.64 | -$1.38 | -$1.65 | -$1.59 |
Caribou Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $2.2M | $3.9M | $2.4M | $1.5M |
| Net Income | -$27.5M | -$26.5M | -$25.1M | -$24.3M |
| Diluted EPS | -$0.30 | -$0.28 | -$0.26 | -$0.24 |
Caribou Biosciences Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $240.4M | $58.3M | $51.2M | $16.3M | $12.4M |
| Current Assets | $391.2M | $260.2M | $338.8M | $219.4M | $145.2M |
| Total Assets | $442.4M | $373.8M | $432.2M | $313.3M | $175.4M |
| Current Liabilities | $25.8M | $28.1M | $28.3M | $30.7M | $25.4M |
| Total Liabilities | $54.5M | $72.9M | $63.8M | $60.4M | $53.2M |
| Shareholders' Equity | $387.8M | $300.9M | $368.4M | $253.0M | $122.2M |
Caribou Biosciences Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$32.5M | -$91.0M | -$93.3M | -$138.2M | -$111.0M |
| Cash From Investing | -$176.4M | -$93.2M | -$68.2M | $86.6M | $102.2M |
| Cash From Financing | $433.4M | $2.1M | $154.3M | $16.7M | $4.8M |
| Free Cash Flow | -$34.6M | -$97.5M | -$104.9M | -$143.1M | -$112.4M |
Figures from Caribou Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Caribou Biosciences financials page for every line item.
Caribou Biosciences Company Profile
| Ticker | CRBU |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Berkeley, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001619856 |
Frequently Asked Questions
What was Caribou Biosciences' revenue in fiscal 2025?
Caribou Biosciences (CRBU) reported revenue of $11.2M for fiscal 2025.
What is Caribou Biosciences' annual revenue history?
Caribou Biosciences' annual revenue by fiscal year: 2021: $9.6M; 2022: $13.9M; 2023: $34.5M; 2024: $10.0M; 2025: $11.2M.
What was Caribou Biosciences' net income in fiscal 2025?
Caribou Biosciences reported net income of -$148.1M for fiscal 2025.
What was Caribou Biosciences' earnings per share (EPS) in fiscal 2025?
Caribou Biosciences' diluted EPS was -$1.59 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Caribou Biosciences generate in fiscal 2025?
Caribou Biosciences generated -$112.4M of free cash flow in fiscal 2025.
What was Caribou Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Caribou Biosciences reported revenue of $1.5M.
How many shares of Caribou Biosciences are outstanding?
Caribou Biosciences reported a weighted average of 101.0 million basic shares outstanding in 2026 Q2.
What is Caribou Biosciences' market cap?
Based on its latest closing price, Caribou Biosciences (CRBU) has a market capitalization of about $47.5M.
When does Caribou Biosciences' fiscal year end?
Caribou Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Caribou Biosciences headquartered?
Caribou Biosciences lists its business address in Berkeley, California in its SEC filings.